Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies)

Vanrenterghem, Yves, Bresnahan, Barbara, Campistol, Josep, Durrbach, Antoine, Grinyó, Josep, Neumayer, Hans-Hellmut, Lang, Philippe, Larsen, Christian P., Mancilla-Urrea, Eduardo, Pestana, José Medina, Block, Alan, Duan, Tao, Glicklich, Alan, Gujrathi, Sheila, Vincenti, Flavio · 2011 · Transplantation

Abstract

BACKGROUND: Cardiovascular disease, the most common cause of death with a functioning graft among kidney transplant recipients, can be exacerbated by immunosuppressive drugs, particularly the calcineurin inhibitors. Belatacept, a selective co-stimulation blocker, may provide a better cardiovascular/metabolic risk profile than current immunosuppressants. METHODS: Cardiovascular and metabolic endpoints from two Phase III studies (BENEFIT and BENEFIT-EXT) of belatacept-based regimens in kidney transplant recipients were assessed at month 12. Each study assessed belatacept in more intensive (MI) and less intensive (LI) regimens versus cyclosporine A (CsA). These secondary endpoints included changes in blood pressure, changes in serum lipids, and the incidence of new-onset diabetes after transplant (NODAT). RESULTS: A total of 1209 patients were randomized and transplanted across the two studies. Mean systolic blood pressure was 6 to 9 mm Hg lower and mean diastolic blood pressure was 3 to 4 mm Hg lower in the MI and LI groups versus CsA (P ≤ 0.002) across both studies at month 12. Non-HDL cholesterol was lower in the belatacept groups versus CsA (P<0.01 MI or LI vs. CsA in each study). Serum triglycerides were lower in the belatacept groups versus CsA (P<0.02 MI or LI vs. CsA in each study). NODAT occurred less often in the belatacept groups versus CsA in a prespecified pooled analysis (P<0.05 MI or LI vs. CsA). CONCLUSIONS: At month 12, belatacept regimens were associated with better cardiovascular and metabolic risk profiles, with lower blood pressure and serum lipids and less NODAT versus CsA. The overall profile of belatacept will continue to be assessed over the 3-year trials.

Overview

Integrity signals

Registry

Crossref · 10.1097/tp.0b013e31820c10eb

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 67 references

Research works printed but not linked: 1

  1. 2003, Introduction, assessment of dyslipidemias, treating dyslipidemias, and research recommendations., Am J Kidney Dis, 41, S11

Cited by

See all 183

Metadata

Authors
Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyó, J., Neumayer, H.-H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., Block, A., Duan, T., Glicklich, A., Gujrathi, S., & Vincenti, F.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • Medical College of Wisconsin (US)
  • Hospital Clínic de Barcelona (ES)
  • Charité – Universitätsmedizin Berlin (DE)
  • Centre Hospitalier Universitaire Henri-Mondor (FR)
  • Emory University (US)
  • Instituto Nacional de Cardiología (MX)
  • University of California, San Francisco (US)
Corresponding author
Vanrenterghem, Yves
Venue
Transplantation
Published
2011-05-15
Volume
91
Issue
9
Pages
976-983
ISSN
0041-1337 (ISSN-L)
OpenAlex
W1976465544
Cited by
183
References
67
Citations by year
2026: 10 · 2025: 9 · 2024: 8 · 2023: 6 · 2022: 10 · 2021: 10 · 2020: 5 · 2019: 11 · 2018: 8 · 2017: 10 · 2016: 11 · 2015: 15 · 2014: 24 · 2013: 13 · 2012: 24
FWCI
16.72
Type
journal article
Language
en
Open access
closed
Locations
  • Transplantation (publishedVersion)
  • PubMed (publishedVersion)
  • UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
Topics
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
belatacept, cyclosporine, kidney transplantation, cardiovascular risk, metabolic risk, blood pressure, serum lipids, non-HDL cholesterol, triglycerides, post-transplant diabetes mellitus, calcineurin inhibitors, immunosuppressive regimens, costimulation blockade
MeSH terms
Abatacept, Adult, Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Immunosuppressive Agents, Lipids, Male, Middle Aged, Risk Factors, Kidney Transplantation, Cyclosporine, Immunoconjugates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies). https://app.cochat.ai/papers/10.1097/tp.0b013e31820c10eb
The paper
Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyó, J., Neumayer, H.-H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., Block, A., Duan, T., Glicklich, A., Gujrathi, S., & Vincenti, F. (2011). Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies). Transplantation. https://doi.org/10.1097/tp.0b013e31820c10eb

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.